Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease by Liz Hanson | Nov 25, 2021 | Uncategorized
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial by Liz Hanson | Nov 10, 2021 | Uncategorized
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study by Liz Hanson | Sep 7, 2021 | Uncategorized
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma by Liz Hanson | Aug 18, 2021 | Uncategorized
FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors by Liz Hanson | Aug 13, 2021 | Uncategorized
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis by Liz Hanson | May 27, 2021 | Uncategorized
